TWI835884B - 神經活性類固醇及其使用方法 - Google Patents

神經活性類固醇及其使用方法 Download PDF

Info

Publication number
TWI835884B
TWI835884B TW108136955A TW108136955A TWI835884B TW I835884 B TWI835884 B TW I835884B TW 108136955 A TW108136955 A TW 108136955A TW 108136955 A TW108136955 A TW 108136955A TW I835884 B TWI835884 B TW I835884B
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
compound
disorder
pharmaceutically acceptable
Prior art date
Application number
TW108136955A
Other languages
English (en)
Chinese (zh)
Other versions
TW202027753A (zh
Inventor
佩拉杜 馬利亞 耶稣 巴蘭可
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202027753A publication Critical patent/TW202027753A/zh
Application granted granted Critical
Publication of TWI835884B publication Critical patent/TWI835884B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW108136955A 2018-10-12 2019-10-14 神經活性類固醇及其使用方法 TWI835884B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745109P 2018-10-12 2018-10-12
US62/745,109 2018-10-12

Publications (2)

Publication Number Publication Date
TW202027753A TW202027753A (zh) 2020-08-01
TWI835884B true TWI835884B (zh) 2024-03-21

Family

ID=68425315

Family Applications (2)

Application Number Title Priority Date Filing Date
TW108136955A TWI835884B (zh) 2018-10-12 2019-10-14 神經活性類固醇及其使用方法
TW113106814A TWI886813B (zh) 2018-10-12 2019-10-14 神經活性類固醇及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113106814A TWI886813B (zh) 2018-10-12 2019-10-14 神經活性類固醇及其使用方法

Country Status (14)

Country Link
US (2) US11634453B2 (enExample)
EP (2) EP4321519B1 (enExample)
JP (2) JP7671244B2 (enExample)
CN (2) CN121045302A (enExample)
AR (1) AR116695A1 (enExample)
AU (2) AU2019357040B2 (enExample)
BR (1) BR112021009428A2 (enExample)
CA (1) CA3115805A1 (enExample)
DK (1) DK3864022T3 (enExample)
ES (1) ES2966055T3 (enExample)
IL (1) IL282183A (enExample)
MX (2) MX2021004159A (enExample)
TW (2) TWI835884B (enExample)
WO (1) WO2020077255A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
EP4321519B1 (en) * 2018-10-12 2026-04-08 Sage Therapeutics, LLC Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ES2296594T3 (es) * 1994-02-14 2008-05-01 Euro-Celtique S.A. Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
NZ298567A (en) 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
HUE039057T2 (hu) 2012-12-18 2018-12-28 Univ Washington Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok
MX2020006599A (es) 2017-12-22 2020-11-06 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
BR112020012761A2 (pt) 2017-12-22 2021-02-17 Sage Therapeutics, Inc. composições e métodos para o tratamento de distúrbios do snc
WO2019154257A1 (zh) 2018-02-11 2019-08-15 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
EP4321519B1 (en) * 2018-10-12 2026-04-08 Sage Therapeutics, LLC Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
CN114729000A (zh) 2019-06-27 2022-07-08 萨奇治疗股份有限公司 用于治疗cns病症的化合物
JP7754725B2 (ja) 2019-06-27 2025-10-15 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法
WO2021188778A2 (en) 2020-03-18 2021-09-23 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US20230250129A1 (en) 2020-06-24 2023-08-10 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
MX2024011494A (es) 2024-09-26
WO2020077255A1 (en) 2020-04-16
EP3864022A1 (en) 2021-08-18
ES2966055T3 (es) 2024-04-18
US20240376144A9 (en) 2024-11-14
JP7671244B2 (ja) 2025-05-01
JP2022504607A (ja) 2022-01-13
EP4321519A3 (en) 2024-05-01
MX2021004159A (es) 2021-09-08
AU2025200422A1 (en) 2025-02-13
US11634453B2 (en) 2023-04-25
TW202027753A (zh) 2020-08-01
AU2019357040A1 (en) 2021-05-20
IL282183A (en) 2021-05-31
CN121045302A (zh) 2025-12-02
EP3864022B1 (en) 2023-09-20
US20210340172A1 (en) 2021-11-04
JP2024040444A (ja) 2024-03-25
DK3864022T3 (da) 2023-12-18
EP4321519B1 (en) 2026-04-08
TW202448479A (zh) 2024-12-16
AU2019357040B2 (en) 2025-03-27
AR116695A1 (es) 2021-06-02
EP4321519A2 (en) 2024-02-14
BR112021009428A2 (pt) 2021-08-31
US20240051987A1 (en) 2024-02-15
TWI886813B (zh) 2025-06-11
CN113166193B (zh) 2025-08-19
CN113166193A (zh) 2021-07-23
CA3115805A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
TWI835884B (zh) 神經活性類固醇及其使用方法
TWI874337B (zh) 神經活性類固醇及其使用方法
TWI835765B (zh) 用於治療cns病症之組合物及方法
TWI772331B (zh) 氧固醇(oxysterol)及其使用方法
TWI892697B (zh) 神經活性類固醇及其組合物
JP6875996B2 (ja) 神経刺激性ステロイド、組成物、およびその使用
TWI896548B (zh) 用於治療cns病症之組合物及方法
TW202320799A (zh) 氧固醇（ｏｘｙｓｔｅｒｏｌ）及其使用方法
TW202233198A (zh) 神經活性類固醇及其組合物
TW202143976A (zh) 神經活性類固醇及其使用方法
JP7534291B2 (ja) ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
TW201930269A (zh) 用於治療cns病症之組合物及方法
RU2796006C2 (ru) Нейроактивные стероиды, замещенные в положении 10 циклической группой, для использования при лечении расстройств цнс
HK40106568A (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
RU2828261C2 (ru) С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения
HK40059417A (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
HK40059417B (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders